LA JOLLA, Calif., Nov. 26, 2013 /PRNewswire/ -- Medical software developer CorTechs Labs, Inc. (CorTechs) announced today that Mr. Guri Stark was appointed Chief Executive Officer on October 28, 2013. This appointment is a prelude to aggressive expansion of CorTechs' unique FDA-cleared image analysis software business in the US and worldwide.
Mr. Stark has over 30 years of experience with proven results in management, software engineering, strategic planning, business development, sales channel strategies and biomedical-engineering. He has led several successful enterprises to develop and deploy software applications for cloud-computing (SaaS), web, mobile and desktop environments in enterprise and consumer markets.
Previously, as the CEO of CloudShare Inc., he was responsible for developing this cloud computing industry leader into a growing solution provider serving over 50% of Fortune 500 companies. Before that, as Vice President and General Manager of the AutoCAD division of Autodesk Inc., Mr. Stark was responsible for developing and delivering over $1 billion of business, including solutions for engineers of all disciplines as well new applications for the "prosumer" markets, based on emerging technologies such as SaaS, cloud computing and mobile platforms.
"There is a vast untapped market for CorTechs' innovative software solutions for volumetric image analysis of brain structures in both stand-alone and Cloud-based business models," according to Mr. Stark, "my goal is to leverage the momentum and growing acceptance of neuroimaging biomarkers to make NeuroQuant® a routine part of clinical radiology practice, providing superior diagnostic capabilities to physicians working in all areas of cognitive impairment, age-related disorders and other neurodegenerative disease."
CorTechs recently closed an investment round to supplement revenue and accelerate expansion activities through 2014.
About CorTechs Labs
CorTechs Labs develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world.
CorTechs' flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the only FDA cleared medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, epilepsy and traumatic brain injury.
SOURCE CorTechs Labs, Inc.